Etosalamide, also known as Ethosalamide, is an antipyretic and analgesics agent.

YM-53601 is a squalene synthase inhibitor (IC50s = 79 and 90 nM in HepG2 cells and rat liver microsomes, respectively).

NLX-101（F-15599） is a novel compound that activates serotonin 5-HT1A receptors with exceptional selectivity, having over 1000-fold higher affinity for this target over other receptors.

TVB-2640 is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity.

BMS-615 BMS615 BMS 615|CAS 2180127-82-4

DDD107498, also known as DDD 498, is a multiple-stage antimalarial agent that inhibits protein synthesis.

JA2-3 (NSC29192) is a potent dose-dependent inhibitor of PARG with IC50 of 0.1 mM.

JA2120 (NSC81474) is a potent inhibitor of PARG with IC50 of 25.7 μM.

Carolacton is a novel MTHFD1 inhibitor,an antibacterial compound,also showed potent activity against COVID-19(SARS-COV-2).

sCGT990 is a novel inhibitor of ENL-YEATS.

PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor.

DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.

nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR).

FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. Anti-dementia properties.

Decoglurant (RO4995819) is a negative allosteric modulator of mGluR2 and mGluR3. Decoglurant is developed as an antidepressant.

CIN-16645 is a cationic lipids useful in the delivery of biologically active agents to cells and tissues.

ATX-081 is an ionizable cationic lipids for RNA or Gene delivery.

ATX-083 is an ionizable cationic lipids for RNA delivery.

ATX-084 is an ionizable cationic lipids for RNA or Gene delivery.

ATX-087 is a novel ionizable cationic lipids for RNA delivery.

GRP-60367 is a first-in-class direct-acting RABV inhibitor.

WP1122 is a candidate drug to treat SARS-COV-2(COVID-19) .